US · Healthcare · Biotechnology
EPS came in at 3.07 against a street estimate of 2.58 — a beat of 19.0%.
Analysts rate Protagonist Therapeutics Inc a strong buy (14 buy, 0 hold, 0 sell out of 14) with an average price target of $178.57.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.93% |
| Farallon Capital Management, L.L.C. | 9.81% |
| RTW INVESTMENTS, LLC | 7.82% |
| Vanguard Portfolio Management, LLC | 5.61% |
| Wellington Management Company LLP | 5.28% |
| UBS Group AG | 5.25% |
| State Street Corp | 5.13% |
| Vanguard Capital Management, LLC | 4.41% |
| Document | Date |
|---|---|
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 license and collaboration revenue was $274.4 million, compared with $4.7 million in Q3 2025. • Q3 2026 net income was $22 | 2026-11-05 |
| Quarterly report · Q2 2026 PROTAGONIST THERAPEUTICS, INC. - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and liquid assets: $420.1 million in | 2026-08-05 |
| Results announced · Q3 2026 PROTAGONIST THERAPEUTICS – Q2 2026 SUMMARY HEADLINE NUMBERS • Net income of $162.8 million for Q2 2026 ($2.29 per diluted share), vs. net loss of $3 | 2026-08-05 |
| Board / officer change · Q2 2026 PROTAGONIST THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 17, 2026 • 64,305,185 shares of common stock outstandi | 2026-06-18 |
| Quarterly report · Q1 2026 PROTAGONIST THERAPEUTICS, INC. — Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Cash and marketable securities (total liquidity): $620.3 million (Marc | 2026-05-05 |
| Results announced · Q2 2026 PROTAGONIST THERAPEUTICS Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $620.3 million in cash, cash equivalents and marketable securit | 2026-05-05 |
| Proxy statement · Q2 2026 PROTAGONIST THERAPEUTICS, INC. — 2026 ANNUAL MEETING PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class I director nom | 2026-04-28 |
| Annual report FY2025 PROTAGONIST THERAPEUTICS, INC. — FORM 10-K SUMMARY (DECEMBER 31, 2025) HEADLINE NUMBERS • Market cap (as of June 30, 2025): $2.9 billion (public flo | 2026-02-25 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Protagonist Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.